Teachers Retirement System of The State of Kentucky decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 4.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 51,246 shares of the life sciences company’s stock after selling 2,170 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Illumina were worth $18,979,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Carroll Financial Associates Inc. bought a new stake in Illumina in the 2nd quarter valued at approximately $32,000. Bainco International Investors bought a new stake in Illumina in the 1st quarter valued at approximately $33,000. CX Institutional lifted its stake in Illumina by 60.3% in the 2nd quarter. CX Institutional now owns 93 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 35 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in Illumina by 49.2% in the 2nd quarter. Valeo Financial Advisors LLC now owns 97 shares of the life sciences company’s stock valued at $36,000 after acquiring an additional 32 shares in the last quarter. Finally, Creative Financial Designs Inc. ADV bought a new stake in Illumina in the 2nd quarter valued at approximately $36,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.
A number of brokerages have recently issued reports on ILMN. TheStreet cut Illumina from a “b” rating to a “c+” rating in a research note on Thursday, August 6th. Evercore ISI cut Illumina from an “in-line” rating to an “underperform” rating and set a $310.00 price objective on the stock. in a research note on Friday, August 7th. SVB Leerink dropped their price objective on Illumina from $370.00 to $360.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Morgan Stanley assumed coverage on Illumina in a research note on Wednesday, September 9th. They set an “equal weight” rating and a $400.00 price objective on the stock. Finally, Argus reissued a “reduce” rating and set a $380.00 target price on shares of Illumina in a report on Friday, September 11th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $344.56.
NASDAQ ILMN traded down $29.72 on Wednesday, reaching $322.47. The stock had a trading volume of 3,409,413 shares, compared to its average volume of 1,160,381. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.76 and a quick ratio of 3.37. The firm has a fifty day moving average of $358.88 and a two-hundred day moving average of $330.78. Illumina, Inc. has a 1-year low of $196.78 and a 1-year high of $404.20. The company has a market cap of $51.42 billion, a P/E ratio of 69.16, a price-to-earnings-growth ratio of 11.40 and a beta of 0.88.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, August 6th. The life sciences company reported $0.62 EPS for the quarter, missing analysts’ consensus estimates of $0.67 by ($0.05). Illumina had a net margin of 20.67% and a return on equity of 19.13%. The firm had revenue of $633.00 million during the quarter, compared to analyst estimates of $682.07 million. During the same period in the prior year, the company earned $1.35 earnings per share. The business’s quarterly revenue was down 24.5% compared to the same quarter last year. Research analysts predict that Illumina, Inc. will post 4.39 EPS for the current fiscal year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Gap Down Stocks
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.